Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review

ConclusionsTreatment of advanced-stage rare tumours with ICI therapy was found to be associated with significant activity in some orphan diseases (e.g., Merkel cell carcinoma) and hepatocellular carcinoma. Several ongoing prospective clinical trials will expand the knowledge on the safety and efficacy of ICI therapy in patients with these rare cancers.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research